3891 Ranchero Drive
Suite 150
Ann Arbor, MI 48108
United States
734 887 3903
https://www.esperion.com
Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full Time Employees: 240
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. Sheldon L. Koenig | President, CEO & Director | 1.28M | N/A | 1966 |
Mr. Eric J. Warren R.Ph. | Chief Commercial Officer | 718.86k | N/A | 1972 |
Mr. Benjamin Halladay M.B.A. | Chief Financial Officer | N/A | N/A | 1986 |
Mr. Glenn P. Brame | Chief Technical Operations Officer | N/A | N/A | 1958 |
Mr. Benjamin O. Looker J.D. | General Counsel & Corporate Secretary | 550.35k | N/A | 1982 |
Tiffany Aldrich M.B.A. | Associate Director of Corporate Communications | N/A | N/A | N/A |
Ms. Betty Jean Swartz | Chief Business Officer | N/A | N/A | N/A |
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
Esperion Therapeutics, Inc.’s ISS Governance QualityScore as of October 1, 2024 is 6. The pillar scores are Audit: 3; Board: 5; Shareholder Rights: 9; Compensation: 6.